Research Output per year
Personal profile
Interests
Dr. Greene completed her PhD within the School of Pharmacy at Queen’s University Belfast, which focused on the therapeutic evaluation of a novel immunomodulatory nanoparticle in models of Acute Respiratory Distress Syndrome. Within her present role as a postdoctoral researcher, Dr. Greene has continued to apply her expertise in nanomedicine, particularly in the field of oncology. She is currently engaged in a US-Ireland R&D Partnership Programme that aims to develop more effective therapies for pancreatic cancer, by combining nanomedicines with agents that can overcome the drug delivery barriers posed by the tumour microenvironment.
Fingerprint Dive into the research topics where Michelle Greene is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 5 Similar Profiles
Nanoparticles
Medicine & Life Sciences
glycolic acid
Chemical Compounds
Nanoconjugates
Chemical Compounds
Sialic Acid Binding Immunoglobulin-like Lectins
Medicine & Life Sciences
Klebsiella Infections
Medicine & Life Sciences
Ubiquitin-Specific Proteases
Medicine & Life Sciences
Tumors
Chemical Compounds
Camptothecin
Medicine & Life Sciences
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Research Output 2014 2019
- 9 Article
Oriented attachment of VNAR proteins, via site-selective modification, on PLGA-PEG nanoparticles enhances nanoconjugate performance
Nogueira, J. C. F., Greene, M. K., Richards, D. A., Furby, A. O., Steven, J., Porter, A., Barelle, C., Scott, C. J. & Chudasama, V., 27 Jun 2019, In : Chemical Communications. 55, 53, p. 7671-7674Research output: Contribution to journal › Article
Open Access
File
glycolic acid
Nanoconjugates
Antigen Receptors
Lactic acid
Antigens
Repurposing of Cetuximab in antibody-directed chemotherapy-loaded nanoparticles in EGFR therapy-resistant pancreatic tumours
McDaid, W. J., Greene, M. K., Johnston, M. C., Pollheimer, E., Smyth, P., McLaughlin, K., Van Schaeybroeck, S., Straubinger, R. M., Longley, D. B. & Scott, C. J., 18 Oct 2019, In : Nanoscale. 13 p.Research output: Contribution to journal › Article
Chemotherapy
Epidermal Growth Factor Receptor
Antibodies
Tumors
Nanoparticles
Clearance of intracellular Klebsiella pneumoniae infection using gentamicin-loaded nanoparticles
Jiang, L., Greene, M. K., Insua, J. L., Sa-Pessoa, J., Small, D. M., Smyth, P., McCann, A., Cogo, F., Bengoechea, J. A., Taggart, C. C. & Scott, C. J., 25 Apr 2018, In : Journal of Controlled Release.Research output: Contribution to journal › Article
Open Access
File
Klebsiella Infections
Klebsiella pneumoniae
Gentamicins
Nanoparticles
Microbial Viability
Generating Next-Generation Antibody-Nanoparticle Conjugates through the Oriented Installation of Non-Engineered Antibody Fragments
Greene, M. K., Richards, D. A., Nogueira, J. C. F., Campbell, K., Smyth, P., Fernańdez, M., Scott, C. J. & Chudasama, V., 14 Aug 2017, In : Chemical Science. 1, p. 79-87 9 p.Research output: Contribution to journal › Article
Open Access
File
Immunoglobulin Fragments
Nanoparticles
Antibodies
Antibody Binding Sites
Ligands
Encapsulation of the p38 MAPK inhibitor GSK 678361A in nanoparticles for inflammatory‐based disease states
Bains, B., Greene, M. K., McGirr, L., Dorman, J., Farrow, S. & Scott, C., 29 May 2016, In : Journal of Interdisciplinary Nanomedicine. 1, 3, p. 85-92Research output: Contribution to journal › Article
Open Access
File
p38 Mitogen-Activated Protein Kinases
Protein Kinase Inhibitors
Nanoparticles
Lipopolysaccharides
Anti-Inflammatory Agents